Alexion Pharmaceuticals Inc (ALXN): Martin Mackay , EVP & Global Head of R&D of Alexion Pharmaceuticals Inc sold 4,097 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $139.81 per share for a total value of $570,283.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 53 shares at $138.65 per share price.On Apr 5, 2016, David Hallal (CEO) sold 1,414 shares at $136.04 per share price.Also, On Mar 4, 2016, Julie O’neill (EVP. Global Operations) sold 651 shares at $149.55 per share price.On Mar 1, 2016, Saqib Islam (EVP, Chief Strat & Port. Off.) sold 905 shares at $138.91 per share price.
Shares of Alexion Pharmaceuticals (ALXN) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -3.3 points or -2.32% at $139.03 with 13,04,226 shares getting traded. Post opening the session at $140.9, the shares hit an intraday low of $137.64 and an intraday high of $142.3 and the price vacillated in this range throughout the day. The company has a market cap of $31,146 M and the number of outstanding shares has been calculated to be 22,40,20,160 shares. The 52-week high of Alexion Pharmaceuticals is $208.88 and the 52-week low is $124.16.
Company has been under the radar of several Street Analysts.Alexion Pharmaceuticals is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 180 from a previous price target of $175 .The Rating was issued on May 9, 2016.Alexion Pharmaceuticals is Downgraded by Robert W. Baird to Neutral while Lowering the Price Target of the company shares to $ 170 from a previous price target of $221 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Mar 8, 2016.Alexion Pharmaceuticals is Initiated by Citigroup to Buy and the brokerage firm has set the Price Target at $165. The Rating was issued on Feb 25, 2016.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.